GLP-1 Receptor Agonists represent a promising therapeutic approach for neurodegenerative diseases. These compounds activate the glucagon-like peptide-1 receptor, which is widely expressed in the brain and exerts neuroprotective effects through multiple signaling pathways.
This page provides comprehensive information about GLP-1 receptor agonists in neurodegeneration, including their mechanisms of action, preclinical and clinical evidence, and therapeutic implications.
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that plays crucial roles in glucose metabolism and has emerged as a attractive target for neurodegenerative disease therapy.
GLP-1 receptor agonists, originally developed for type 2 diabetes, have shown neuroprotective properties in numerous preclinical studies and are now being investigated in clinical trials for Alzheimer's disease and Parkinson's disease.
Research on GLP-1R in neurodegeneration began with observations that GLP-1 signaling could protect neurons from various insults. Early animal studies demonstrated that GLP-1 receptor agonists could improve memory, reduce amyloid plaques, and decrease neuroinflammation.
Key milestones include the discovery of GLP-1R expression in the brain, demonstration of neuroprotective signaling pathways, and successful preclinical studies in Alzheimer's and Parkinson's disease models. Several GLP-1 receptor agonists including liraglutide, exenatide, and dulaglutide are now in clinical trials for neurodegenerative diseases.
The glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor (GPCR) expressed in the pancreas and brain that plays a crucial role in glucose metabolism and has emerged as a promising therapeutic target for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
The GLP-1R gene (located on chromosome 6p21) encodes a 463-amino acid class B GPCR protein [1]. The receptor consists of:
GLP-1 receptors are widely expressed in the central nervous system, with particularly high expression in:
This widespread distribution suggests GLP-1 signaling participates in multiple brain functions beyond glucose regulation.
Upon GLP-1 binding, GLP-1R activates Gαs protein, leading to:
GLP-1R activation engages multiple signaling pathways relevant to neuroprotection:
GLP-1R can also signal through β-arrestin pathways independent of G protein coupling, which may contribute to its neuroprotective effects [3].
Several factors make GLP-1R an attractive target for Alzheimer's disease:
Animal studies have demonstrated that GLP-1 receptor agonists:
Multiple clinical trials are evaluating GLP-1 receptor agonists in Alzheimer's disease:
| Agent | Trial Phase | Status | Outcome Measures |
|-------|-------------|--------| Liragl|----------------|
utide | Phase 2 | Completed | Cognition, brain, biomarkers volume |
| Exenatide | Phase 2 | Completed | Motor| Semaglut and cognitive outcomes |
ide | Phase 3 | Ongoing | Clinical dementia rating |
| Dulaglutide | Phase 2 | Recruiting | Cognitive function |
The ELAD study (Evaluating Liraglutide in Alzheimer's Disease) showed some promising trends in cognition, though primary endpoints were not met [10]. The ExenD-CPD trial demonstrated good safety and some motor benefits in Parkinson's disease [11].
GLP-1 receptor agonists have demonstrated a favorable safety profile in clinical use for diabetes:
A key question for CNS applications is whether GLP-1 receptor agonists can cross the blood-brain barrier. Current evidence suggests:
GLP-1R activation reduces neuroinflammation through:
GLP-1 signaling enhances autophagy and the clearance of toxic proteins:
GLP-1R signaling preserves synaptic integrity:
GLP-1 receptor agonists may be particularly effective in combination with:
Identifying predictors of response will be important:
[1] Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
[2] Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport. 2009;20(13):1161-1166.
[3] Liu J, Wu Z, Han D, et al. G protein-independent signaling pathways of GLP-1 receptor. Front Endocrinol (Lausanne). 2023;14:1134320.
[4] Hölscher C. Novel dual GLP-1/GIP receptor agonists are neuroprotective in animal models of Alzheimer's disease. J Diabetes Res. 2020;2020:7125876.
[5] McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice. Neuropharmacology. 2014;86:43-54.
[6] McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide reduces amyloid pathology in APP/PS1 mice. J Alzheimers Dis. 2011;27(4):853-865.
[7] Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation. J Mol Neurosci. 2010;42(2):215-224.
[8] Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by high glucose. J Neurochem. 2008;105(3):724-732.
[9] Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263-269.
[10] Femkle C, et al. Liraglutide in Alzheimer's disease: results from the ELAD study. J Prev Alzheimers Dis. 2019;6(1):S20.
[11] Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675.